Compare Organon & Co. Common Stock (OGN) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Vanguard Total Stock Market Index Fund ETF trades at $376.1 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 637.1× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vanguard Total Stock Market Index Fund ETF for 132 Days on average.
| OGN | VTI | |
|---|---|---|
Market Cap | $3.61B | $2.30T |
Volume | 1,808,049 | 3,256,421 |
Sector | Health | — |
52-Week High | $13.81 | $384.30 |
52-Week Low | $5.70 | $311.68 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VTI trades at $381.32, down slightly by 0.07% today, with strong technical momentum as moving averages signal bullish conditions. The ETF maintains broad U.S. equity exposure across 3,500+ stocks, though concentration in top holdings remains a diversification consideration. Recent dividend activity and positive media coverage highlight its role in long-term portfolios.
Outlook remains favorable for buy-and-hold investors seeking diversified U.S. market exposure, with risks including market concentration and economic sensitivity. Technical strength supports near-term upside, while fundamental breadth provides stability across market cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
